---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-057804"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2026-08-18T23:56:38+00:00"
generated_at: "2026-08-19T10:05:32.817895+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience receives Nasdaq delisting notice for negative stockholders' equity

## Summary
- Stockholders' equity was ($497,307) as of June 30, 2026, below Nasdaq's $2.5M minimum requirement.
- Company has until Oct 2, 2026 to submit a compliance plan; Nasdaq may grant extension to Feb 14, 2027.
- Common stock continues trading on Nasdaq under 'SKYE'; no immediate effect on listing.
- Company evaluating alternatives to regain compliance; no assurance of success.
- Also disclosed proposed acquisition of Redx Pharma Limited (Transaction Agreement dated Aug 14, 2026).

## SEC filing metadata
- accession: 0001628280-26-057804
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2026-08-18T23:56:38+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/0001628280-26-057804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/skye-20260818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-057804
- JSON: https://secwatch.observer/filing/0001628280-26-057804.json
- Plain text: https://secwatch.observer/filing/0001628280-26-057804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.